16 results about "Cyclosporins" patented technology

The invention provides pharmaceutical compositions comprising about 0.05 to 0.1% (w / v) cyclosporine dissolved in 1-perfluorobutyl-pentane for use in the topical treatment of dry eye disease and provides for dosing and treatment methods thereof. The invention further provides kits comprising such compositions.

The application discloses a liposome drug carrier with mucosal adhesion, a preparation method and application thereof, and specifically, the drug carrier is DSPE-PEG-PBA, which can be used for loading cyclosporine A and crocin I, and the carrier of the application is used for loading cyclosporine A and crocin I. The liposome loaded with the two drugs has good stability and adhesion, can inhibit the side effect of cyclosporine A on the increase of ROS level, and has a wide application prospect in the treatment of inflammation and epithelial tissue damage.

This invention relates to the field of insect control, specifically to the Paecilomyces lilacinus strain XI-5, and the extraction and identification of crude toxins produced by secondary metabolites of Paecilomyces lilacinus strain XI-5. This invention confirms that the secondary metabolites of Paecilomyces lilacinus strain XI-5 produce cyclosporine C. Cyclosporine C has a stomach poison effect on adult whiteflies. Twenty-four hours after application, the LC50 concentration of cyclosporine C against adult whiteflies was 31.75 µg / ml; compared to the control group, the LC30 concentration of cyclosporine C resulted in a decrease in oviposition / fertility in female whiteflies.

The application discloses application of pulegone as an effective component in an immunosuppressant, and the pulegone with significant calcineurin (CN) inhibiting activity is screened from the Schleichera oleosa Kurz, the immunosuppressive effect of the pulegone is equivalent to that of cyclosporine A which is widely used in clinic, mechanism research shows that the pulegone targets CN / NFAT signal path to play the immunosuppressive activity, and the pulegone has very weak cytotoxicity to spleen cells, and is a high-efficiency and low-toxicity immunosuppressant.

Provided herein are combinations comprising: 1) acoltremon; and 2) lifitegrast or cyclosporin, or a pharmaceutically acceptable salt thereof. The combinations are useful for treating dry eye or dysfunctional tear syndrome, or a sign or symptom thereof.

The present invention relates to a nanoemulsion ophthalmic composition and a preparation method thereof, wherein the nanoemulsion ophthalmic composition is obtained by mixing cyclosporine, castor oil, hydrophilic and hydrophobic emulsifiers, menthol, and an aqueous solvent, and thus exhibits excellent stability as well as ameliorating ocular irritation such as a feeling of grittiness, blurry vision, and the like.

Provided herein are combinations comprising: 1) acoltremon; and 2) lifitegrast or cyclosporin, or a pharmaceutically acceptable salt thereof. The combinations are useful for treating dry eye or dysfunctional tear syndrome, or a sign or symptom thereof.

A blood test method includes: a preparation step of preparing whole blood collected from a subject; a pretreatment step for preparing a sample for analysis by pretreating the whole blood; a separation step in which the sample for analysis is separated by components using a liquid chromatograph; and an analysis step for analyzing the separated component using a mass spectrometry device, the subject being administered with a first immunosuppressant comprising at least one substance selected from the group consisting of tacrolimus, cyclosporin A, everolimus, and sirolimus, and with a second immunosuppressant comprising at least one substance selected from the group consisting of cyclosporin A, everolimus, and sirolimus. The second immunosuppressive agent contains at least one substance selected from the group consisting of mycophenolic acids and metabolites thereof, the separated component contains the first immunosuppressive agent and the second immunosuppressive agent, and when the first immunosuppressive agent is analyzed as a target component in the analysis using the mass spectrometry device, the first immunosuppressive agent is separated from the target component, and when the second immunosuppressive agent is separated from the target component, the second immunosuppressive agent is separated from the target component. When the first immunosuppressive agent is analyzed as a target component, analysis is performed in a positive ion pattern, and when the second immunosuppressive agent is analyzed as a target component, analysis is performed in a negative ion pattern.

The present invention relates to a cyclosporine emulsion and preparation method thereof, in particular to an oil-in-water cyclosporine emulsion, comprising an interfacial stabilizer, wherein the interfacial stabilizer comprises a combination of polyethylene glycol 15-hydroxystearate and a phospholipid. The emulsion has long-term stability in terms of the pH value, particle size and encapsulation rate.

The present invention provides pharmaceutical compositions for the topical treatment of dry eye disease comprising about 0.05 to 0.1% (w / v) cyclosporin dissolved in 1-perfluorobutyl-pentane, and methods of administering and treating the same. The invention also provides kits comprising such compositions.

The present invention provides a dispersion composition comprising: a dispersion medium; and particles comprising a target substance. The dispersion composition comprises at least one surfactant at a concentration above the critical micelle concentration, and does not comprise a solubilizer. The target substance is cyclosporin A, and satisfies the previously defined S-parameter > 1.

The present invention relates to cyclosporin compositions and methods of use. The present invention discloses a compound having a structure of formula I: (I) a stereoisomer thereof, or a pharmaceutically acceptable salt of any one of the compound or the stereoisomer thereof; wherein: L1 is a C1 to C4 alkylene group optionally substituted by one or more F; r is PEG having 40 to 50 ethylene oxide units, wherein the PEG comprises a linker L2; and L2 is a C1-6 unsubstituted heteroalkylene group having one or two nitrogen atoms. The present invention also discloses the use of the compound, the stereoisomer thereof, or the pharmaceutically acceptable salt of any one of the compound or the stereoisomer thereof in the preparation of a medicament for treating a disease associated with neutrophil-mediated inflammation in a target tissue of a mammalian subject in need thereof.

The present invention provides pharmaceutical compositions for the topical treatment of dry eye disease comprising about 0.05 to 0.1% (w / v) cyclosporin dissolved in 1-perfluorobutyl-pentane, and methods of administering and treating the same. The invention also provides kits comprising such compositions.